Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
1288 Results for "
EGF-R
" in MedChemExpress (MCE) Product Catalog:
Products (1288)
1288 Results for "EGF-R" in MCE Product Catalog:
Research Areas:
QCA570 is a pan-BET-BRD PROTAC degrader. QCA570 degrades BRD2/3/4 and BRDT via cereblon and the ubiquitin-proteasome pathway, inhibits the expression of c-MYC, EZH2 and Mcl-1, induces tumor cell apoptosis, cycle arrest and regression, and exerts a synergistic inhibitory effect on Osimertinib (HY-15772)-resistant EGFR-mutant non-small cell lung cancer. QCA570 can be used in the research of acute myeloid leukemia, acute lymphoblastic leukemia, bladder cancer and non-small cell lung cancer .
Cat. No.: HY-178004
VEGFR-2-IN-73 is a potent and selective VEGFR-2 inhibitor, showing selectively inhibition of VEGFR-2 (IC50 = 0.0787 μM) over EGFR (IC50 = 1.31 μM). VEGFR-2-IN-73 demonstrates potent antiproliferative activity across multiple cancer cell lines. VEGFR-2-IN-73 induces G2/M and Pre-G1 phase arrest and significantly enhances apoptosis. VEGFR-2-IN-73 can be used in cancer research, such as colorectal carcinoma, hepatocellular carcinoma, and breast cancer .
Cat. No.: HY-189200
CAS No.: 3006101-94-3
Target:
Research Areas:
AZ'4331 is an orally active pan-TEAD family inhibitor, with an IC50 of 0.381 μM against TEAD1, 0.020 μM against TEAD2, 0.014 μM against TEAD3, and 0.031 μM against TEAD4. AZ'4331 slows cell cycle progression. AZ'4331 exerts effects in cancer xenograft models with dysregulated Hippo pathway. AZ'4331 can be used to study cancers with altered Hippo pathways, including mesothelioma, head and neck squamous cell carcinoma, and EGFR-mutant non-small cell lung cancer .
Cat. No.: HY-N20662
CAS No.: 2779545-15-0
Cat. No.: HY-N2441
CAS No.: 74805-90-6
Category:
Ophiopogon japonicus (L. f.) Ker-Gawl. Liliaceae Flavonoids Phenols Polyphenols Plants Disease Research Fields Inflammation/Immunology Other Flavonoids
Target:
Cat. No.: HY-P991748
Cat. No.: HY-P706169
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: EGFR; Epidermal Growth Factor Receptor Variant EX12_14del; Prev. ERBB; Cell Proliferation-Inducing Protein 61; ERBB1; Cell Growth Inhibiting Protein 40; ERRP; Receptor Protein-Tyrosine Kinase; Receptor Tyrosine-Protein Kinase ErbB-1; Alternative Protein E
Species:
Others
Source:
E. coli
Cat. No.: HY-L080
106 compounds
Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer.
There are several different types of targeted therapy. The most common types are small-molecule drugs and monoclonal antibodies. Small-molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells, while monoclonal antibodies are usually used for targets that are located outside the cells. Because of high specificity, low side effect and potent anticancer activity, targeted therapy has become the mainstream of new anti-tumor drugs. Various targeted therapies have been approved by FDA and used in the treatment of diseases.
MCE carefully collects a unique of 106 targeted therapy drugs used in cancer treatment. MCE Targeted therapy drug library is a useful tool for the research of targeted therapy.
Cat. No.: HY-122585
CAS No.: 2138321-18-1
proMMP-9 inhibitor-3c (compound 3c) is a potent proMMP-9 inhibitor. proMMP-9 inhibitor-3c is specific for binding to the proMMP-9 hemopexin-like domain (Kd=320 nM). proMMP-9 inhibitor-3c disruption of MMP-9 homodimerization prevents association of proMMP-9 with both α4β1 integrin and CD44 and results in the dissociation of EGFR. This disruption results in decreased phosphorylation of Src and its downstream target proteins focal adhesion kinase (FAK) and paxillin (PAX) .
Cat. No.: HY-124398
CAS No.: 591242-70-5
GL-1196 is an inhibitor of PAK4. GL-1196 can suppress the proliferation and invasion of gastric cancer cells. GL-1196 inhibits PAK4-mediated signaling pathways. GL-1196 can hinder the proliferation of human gastric cancer cells through suppressing PAK4/c-Src/EGFR/CyclinD1 and CDK4/6. GL-1196 can reduce filamentous pseudopodia formation and induce filamentous pseudopodia formation and promote cell elongation in SGC7901 and BGC823 cells. GL-1196 can be studied in anti-cancer research .
Cat. No.: HY-156470
CAS No.: 3009081-73-3
Target:
Trk Receptor Anaplastic lymphoma kinase (ALK) c-Kit EGFR Pim Casein Kinase Checkpoint Kinase (Chk) CDK Apoptosis
Research Areas:
Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that shows good enzyme inhibitory activity against TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2. Multi-kinase-IN-6 reveals antiproliferative activity against MCF7, HCT116 and EKVX with IC50 values of 3.36 μM, 1.40 μM and 3.49 μM, respectively. Multi-kinase-IN-6 shows cell cycle arrest at the G1/S phase and G1 phase in MCF7 and HCT116 cells with good apoptotic effect .
Cat. No.: HY-170704
CAS No.: 1480940-53-1
Target:
Research Areas:
DSPE-PEG2000-TCO is a click chemistry coupling partner. DSPE-PEG2000-TCO undergoes a reverse electron-demand Diels-Alder click reaction to form a covalent linkage with tetrazine-modified Cetuximab (HY-P9905). DSPE-PEG2000-TCO maintains the stability of lipid nanoparticles (LNPs) and has high mRNA encapsulation efficiency, which supports cellular uptake and mRNA transfection. DSPE-PEG2000-TCO is used to prepare EGFR-targeted and APN-targeted mRNA-loaded LNPs, mediating receptor-dependent endocytosis, mRNA delivery, and intestinal epithelial transcytosis .
Cat. No.: HY-179098
Multi-target kinase-IN-8 (3d) is an anti-cancer agent. Multi-target kinase-IN-8 exhibits inhibitory activity against various protein kinases (B-Raf V600E (IC50 = 0.078 µg/mL), c-Met (IC50 = 0.405 µg/mL), Pim-1 (IC50 = 1.053 µg/mL), EGFR WT (IC50 = 0.177 µg/mL), VEGFR-2 (IC50 = 0.275 µg/mL)). Multi-target kinase-IN-8 can induce cell cycle arrest and promote early and late apoptosis. Multi-target kinase-IN-8 is commonly used in cancer research .
Cat. No.: HY-187240
Target:
Research Areas:
DMG-PEG1000-GE11 is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 1000 Da, and GE11 peptide (YHWYGYTPQNVI) (HY-P10128) as the terminal targeting/functional ligand. DMG-PEG1000-GE11 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against EGFR (HER1) on the surface of various epithelial tumor cells (lung cancer, breast cancer, colorectal cancer, head and neck cancer).
Cat. No.: HY-187240A
Target:
Research Areas:
DMG-PEG2000-GE11 is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and GE11 peptide (YHWYGYTPQNVI) (HY-P10128) as the terminal targeting/functional ligand. DMG-PEG2000-GE11 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against EGFR (HER1) on the surface of various epithelial tumor cells (lung cancer, breast cancer, colorectal cancer, head and neck cancer).
Cat. No.: HY-187240B
Target:
Research Areas:
DMG-PEG3400-GE11 is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 3400 Da, and GE11 peptide (YHWYGYTPQNVI) (HY-P10128) as the terminal targeting/functional ligand. DMG-PEG3400-GE11 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against EGFR (HER1) on the surface of various epithelial tumor cells (lung cancer, breast cancer, colorectal cancer, head and neck cancer).
Cat. No.: HY-187240C
Target:
Research Areas:
DMG-PEG5000-GE11 is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 5000 Da, and GE11 peptide (YHWYGYTPQNVI) (HY-P10128) as the terminal targeting/functional ligand. DMG-PEG5000-GE11 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against EGFR (HER1) on the surface of various epithelial tumor cells (lung cancer, breast cancer, colorectal cancer, head and neck cancer).
Cat. No.: HY-187312
Target:
Research Areas:
DOPE-PEG1000-GE11 is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 1000 Da, and GE11 peptide (YHWYGYTPQNVI) (HY-P10128) as the terminal targeting/functional ligand. DSG-PEG2000-GE11 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against EGFR (HER1) on the surface of various epithelial tumor cells (lung cancer, breast cancer, colorectal cancer, head and neck cancer).
Cat. No.: HY-187312A
Target:
Research Areas:
DOPE-PEG2000-GE11 is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and GE11 peptide (YHWYGYTPQNVI) (HY-P10128) as the terminal targeting/functional ligand. DOPE-PEG2000-GE11 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against EGFR (HER1) on the surface of various epithelial tumor cells (lung cancer, breast cancer, colorectal cancer, head and neck cancer).
Cat. No.: HY-187312B
Target:
Research Areas:
DOPE-PEG3400-GE11 is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 3400 Da, and GE11 peptide (YHWYGYTPQNVI) (HY-P10128) as the terminal targeting/functional ligand. DOPE-PEG3400-GE11 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against EGFR (HER1) on the surface of various epithelial tumor cells (lung cancer, breast cancer, colorectal cancer, head and neck cancer).
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
